AN ACT CONCERNING INSURANCE COVERAGE FOR THE SCREENING AND TREATMENT OF PROSTATE CANCER.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

Section 1. Section 38a-492g of the general statutes is repealed and the following is substituted in lieu thereof (Effective January 1, 2012):

[Each] On and after January 1, 2012, and until December 31, 2013, each individual health insurance policy providing coverage of the type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-469 delivered, issued for delivery, renewed, amended or continued in this state on or after January 1, 2000, shall provide coverage for:

(1) Laboratory and diagnostic tests, including, but not limited to, prostate specific antigen (PSA) tests, to screen for prostate cancer for men who are symptomatic or whose biological father or brother has been diagnosed with prostate cancer, and for all men fifty years of age or older; and

(2) The treatment of prostate cancer, provided such treatment is medically necessary and in accordance with guidelines established by the National Comprehensive Cancer Network, the American Cancer Society or the American Society of Clinical Oncology.
Sec. 2. Section 38a-518g of the general statutes is repealed and the following is substituted in lieu thereof (Effective January 1, 2012):

[Each] On and after January 1, 2012, and until December 31, 2013, each group health insurance policy providing coverage of the type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-469 delivered, issued for delivery, renewed, amended or continued in this state [on or after January 1, 2000,] shall provide coverage for:

(1) Laboratory and diagnostic tests, including, but not limited to, prostate specific antigen (PSA) tests, to screen for prostate cancer for men who are symptomatic [.] or whose biological father or brother has been diagnosed with prostate cancer, and for all men fifty years of age or older; [.] and

(2) The treatment of prostate cancer, provided such treatment is medically necessary and in accordance with guidelines established by the National Comprehensive Cancer Network, the American Cancer Society or the American Society of Clinical Oncology.

This act shall take effect as follows and shall amend the following sections:

<table>
<thead>
<tr>
<th>Section</th>
<th>Effective Date</th>
<th>Repealed Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>January 1, 2012</td>
<td>38a-492g</td>
</tr>
<tr>
<td>Sec. 2</td>
<td>January 1, 2012</td>
<td>38a-518g</td>
</tr>
</tbody>
</table>

INS Joint Favorable Subst.